During the past decade, Digestive Health Specialists of the Southeast conducted 52 clinical trials. In the 10-year time frame, 52 clinical trials started and 25 clinical trials were completed, i.e. on average, 48.1% percent of trials that started reached the finish line to date. In the past 5 years, 23 clinical trials started and 22 clinical trials were completed. i.e. 95.7% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Digestive Health Specialists of the Southeast" #1 sponsor was "Gilead Sciences" with 8 trials, followed by "Pfizer" with 7 trials sponsored, "Allergan" with 5 trials sponsored, "Eli Lilly and Company" with 5 trials sponsored and "Evoke Pharma" with 5 trials sponsored. Other sponsors include 28 different institutions and companies that sponsored additional 29 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Digestive Health Specialists of the Southeast" #1 collaborator was "Arena is a wholly owned subsidiary of Pfizer" with 4 trials as a collaborator, "Gilead Sciences" with 3 trials as a collaborator, "Galapagos NV" with 1 trials as a collaborator, "Novo Nordisk A/S" with 1 trials as a collaborator and "Parexel" with 1 trials as a collaborator. Other collaborators include -3 different institutions and companies that were collaborators in the rest 7 trials.

According to Clinical.Site data, the most researched conditions in "Digestive Health Specialists of the Southeast" are "Ulcerative Colitis" (16 trials), "Crohn's Disease" (8 trials), "Gastroparesis" (6 trials), "Diabetes Mellitus" (5 trials) and "Diabetic Gastroparesis" (5 trials). Many other conditions were trialed in "Digestive Health Specialists of the Southeast" in a lesser frequency.

Most popular intervention types in "Digestive Health Specialists of the Southeast" are "Drug" (56 trials), "Biological" (2 trials), "Device" (2 trials), "Other" (2 trials) and "Diagnostic Test" (1 trials). Other intervention types were less common.

The name of intervention was led by "Placebo" (34 trials), "Etrasimod" (6 trials), "Filgotinib" (4 trials), "Mirikizumab" (4 trials) and "Relamorelin" (4 trials). Other intervention names were less common.

The vast majority of trials in "Digestive Health Specialists of the Southeast" are 59 trials for "All" genders, 1 trials for "Female" genders and 1 trials for "Male" genders.

Currently, there are NaN active trials in "Digestive Health Specialists of the Southeast". undefined are not yet recruiting, 14 are recruiting, 10 are Active, not recruiting, and 1 are Enrolling by invitation. In total, there were 25 completed trials in Digestive Health Specialists of the Southeast, undefined suspended trials, and 9 terminated clinical trials to date.

Out of the total trials that were conducted in Digestive Health Specialists of the Southeast, 0 "Phase 1" clinical trials were conducted, 23 "Phase 2" clinical trials and 33 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 2 trials, and there were also 0 trials that are defined as “Not Applicable".